Lung Cancer

Kidney Cancer Metastases in Lung May Hide Undiagnosed Primary Lung Cancer

Kidney Cancer Metastases in Lung May Hide Undiagnosed Primary Lung Cancer

By

Patients with metastatic kidney cancer may also have an primary lung cancer that has gone gone undiagnosed.

Nasal Biomarker in Smokers Could Predict Lung Cancer

Nasal Biomarker in Smokers Could Predict Lung Cancer

By

Novel diagnostic test determines whether suspicious lung lesions or nodules are malignant disease from a sample obtained via nasal swab.

Proportion of Never-Smokers With NSCLC Is on the Rise

Proportion of Never-Smokers With NSCLC Is on the Rise

By

A study of a large, diverse patient population appears to show an increasing incidence of lung cancer in patients who have never smoked tobacco.

Patients with Lung Cancer Do Not Benefit from Statins

Patients with Lung Cancer Do Not Benefit from Statins

By

Statins provide no benefits, or adverse effects, in patients with lung cancer, according to a phase 3 trial.

Risk of Lung Cancer Increases After Radiation for Breast Cancer

Risk of Lung Cancer Increases After Radiation for Breast Cancer

By

Treatment with radiation therapy for invasive breast cancer may place East Asian women at a greater risk of developing second primary lung cancer (SPLC).

NSCLC: Pathway Navigation Program Lowers Costs of Care

NSCLC: Pathway Navigation Program Lowers Costs of Care

By

A clinical pathways navigation program for patients with non-small cell lung cancer significantly reduced cost of care while preserving clinical outcomes.

FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC

FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC

By

Ceritinib has been granted Priority Review as a first-line treatment for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer.

E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use

E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use

By

E-cigarettes and replacement nicotine therapy deposit fewer harmful chemicals in the body that smoking.

Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments

Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments

By

Elderly with NSCLC have lower incidence of esophagitis, can tolerate aggressive radiation therapy.

Annual Screening of High-Risk Smokers Only More Cost-effective Than Current Methods

Annual Screening of High-Risk Smokers Only More Cost-effective Than Current Methods

By

Annual lung cancer screening of only high-risk smokers more cost-effective than current methods.

Lung Cancer Screening Rates Low Among Present and Former Smokers

Lung Cancer Screening Rates Low Among Present and Former Smokers

Researchers estimate that out of the 6.8 million current and former smokers eligible for lung cancer screening in 2015, only a fraction received it.

New Study Shows Standard of Care for NSCLC Patients Leads to Improved Overall Survival

New Study Shows Standard of Care for NSCLC Patients Leads to Improved Overall Survival

By

There are a growing number of NSCLC patients with advanced disease who are opting to forgo treatment despite the fact that receiving standard of care treatment leads to a higher OS.

Nut Consumption Inversely Associated With Lung Cancer Risk

Nut Consumption Inversely Associated With Lung Cancer Risk

By

A higher consumption of nuts was associated with a lower overall risk for developing lung cancer irrespective of smoking status.

Many VHA Patients Eligible for Lung Cancer Screening

Many VHA Patients Eligible for Lung Cancer Screening

Second study shows increase in lung cancer screening from 1.3 to 2.1 percent from 2010 to 2015

Addition of Bevacizumab to Chemo Improves PFS in Extensive SCLC

Addition of Bevacizumab to Chemo Improves PFS in Extensive SCLC

By

The addition of bevacizumab to first-line treatment with cisplatin plus etoposide improved PFS, but not OS, with an acceptable toxicity profile in patients with extensive-disease SCLC.

Use of Upfront TKIs Linked to Inferior OS in EGFR+ NSCLC With Brain Metastases

Use of Upfront TKIs Linked to Inferior OS in EGFR+ NSCLC With Brain Metastases

By

Treatment options for brain metastases in patients with EGFR-mutant NSCLC include SRS, WBRT, and EGFR TKIs. In this study, researchers sought to determine the optimal treatment approach of those who develop brain metastases and have not received EFGR TKIs.

First-line Ceritinib Improves PFS vs Chemo in Advanced ALK-rearranged NSCLC

First-line Ceritinib Improves PFS vs Chemo in Advanced ALK-rearranged NSCLC

By

Ceritinib is a kinase inhibitor indicated for the treatment of patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib; in this study, researchers determined the efficacy of ceritinib in patients with untreated ALK-rearranged NSCLC.

Many Advanced NSCLC Patients Not Getting Helpful Treatment

Many Advanced NSCLC Patients Not Getting Helpful Treatment

Study found 21 percent of those with late-stage non-small cell lung cancer went without therapy, even though it could boost survival.

Tobacco Counseling for Youth, Adults Reduces Smoking Prevalence

Tobacco Counseling for Youth, Adults Reduces Smoking Prevalence

Annual counseling could reduce prevalence and prevent many smoking-attributable fatalities.

No Differences in Lung Cancer Mutations Between White, Black Patients

No Differences in Lung Cancer Mutations Between White, Black Patients

By

Analyses of lung tumor specimens were used to determine whether mutational profiles of lung cancers differ between black and white patients. Such differences could explain differences in prognosis and lead to reductions in outcomes disparities.

Lung Cancer Navigator App Aims to Help Patients Understand Disease

Lung Cancer Navigator App Aims to Help Patients Understand Disease

By

Lung Cancer Navigator, a mobile, customizable app from LUNGEVITY, helps patients with lung cancer better understand their disease, manage medications, track symptoms, and access support.

Considerable Shifts in NSCLC Treatment With Modest Gains in Survival

Considerable Shifts in NSCLC Treatment With Modest Gains in Survival

By

Investigators report on trends in treatment of advanced-stage NSCLC from 2000 to 2011, including impact on survival and total Medicare spending.

Delayed Adjuvant Chemotherapy Not Associated With Survival in NSCLC

Delayed Adjuvant Chemotherapy Not Associated With Survival in NSCLC

By

Study evaluated differences in survival with respect to the time interval between tumor resection and initiation of postoperative chemotherapy in patients with NSCLC.

Comparison of Three Information Sources for Smoking Information in Electronic Health Records

Comparison of Three Information Sources for Smoking Information in Electronic Health Records

[Cancer Informatics] This research examinbed independent and joint performance of retrieving smoking status through different sources and compared the performance of retrieving smoking strength information from narrative text and PPI.

Stepped Psychological Care for Patients with Head and Neck or Lung Cancer

Stepped Psychological Care for Patients with Head and Neck or Lung Cancer

By

For patients with head and neck or lung cancer, stepped care programs may offer a more affordable yet effective approach.

The evolution of the diminishing role of extrapleural pneumonectomy in the surgical management of malignant pleural mesothelioma

The evolution of the diminishing role of extrapleural pneumonectomy in the surgical management of malignant pleural mesothelioma

[OncoTargets and Therapy] The surgical approach that offers the best outcomes for malignant pleural mesothelioma management is still debated. This research examines the efficacy of surgical treatment.

Cisplatin-etoposide and Carboplatin-paclitaxel With RT Comparable for Stage III Lung Cancer

Cisplatin-etoposide and Carboplatin-paclitaxel With RT Comparable for Stage III Lung Cancer

By

Carboplatin-paclitaxel with concurrent RT has comparable efficacy with cisplatin-etoposide plus RT in patients with stage III NSCLC.

Atezolizumab Prolongs Survival vs Docetaxel in Previously Treated NSCLC

Atezolizumab Prolongs Survival vs Docetaxel in Previously Treated NSCLC

By

The efficacy and safety of atezolizumab in patients with previously treated NSCLC was evaluated in the OAK trial, an open-label, pivotal, phase 3 study, the results of which were recently published.

Survival Not Better With Onartuzumab Plus Erlotinib for MET-Positive NSCLC

Survival Not Better With Onartuzumab Plus Erlotinib for MET-Positive NSCLC

By

Results of the METLung trial are presented. In this trial, researchers evaluated the efficacy and safety of onartuzumab in patients with advanced NSCLC selected by MET immunohistochemistry.

Osimertinib New Standard of Care for T790M+ Advanced NSCLC

Osimertinib New Standard of Care for T790M+ Advanced NSCLC

By

A study presented at the World Conference on Lung Cancer compared progression-free survival after treatment with osimertinib with that of platinum therapy plus pemetrexed in a select group of patients with T790M-positive advanced NSCLC.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs